{"id":"NCT02762578","sponsor":"Novo Nordisk A/S","briefTitle":"Comparing Efficacy and Safety of Insulin Degludec/Insulin Aspart and BIAsp 30 in Subjects With Type 2 Diabetes","officialTitle":"A Trial Comparing Efficacy and Safety of Insulin Degludec/Insulin Aspart and BIAsp 30 in Subjects With Type 2 Diabetes BOOST: INTENSIFY PREMIX/ALL 2","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2016-05-03","primaryCompletion":"2017-05-19","completion":"2017-06-19","firstPosted":"2016-05-05","resultsPosted":"2018-12-07","lastUpdate":"2019-04-02"},"enrollment":543,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Diabetes","Diabetes Mellitus, Type 2"],"interventions":[{"type":"DRUG","name":"insulin degludec/insulin aspart","otherNames":[]},{"type":"DRUG","name":"biphasic insulin aspart","otherNames":[]}],"arms":[{"label":"IDegAsp BID","type":"EXPERIMENTAL"},{"label":"BIAsp 30 BID","type":"ACTIVE_COMPARATOR"}],"summary":"This trial is conducted in Asia. The aim of this trial is to compare efficacy and safety of insulin degludec/insulin aspart and BIAsp 30 in subjects with type 2 diabetes.","primaryOutcome":{"measure":"Change From Baseline in HbA1c (%) (Glycosylated Haemoglobin)","timeFrame":"At 26 weeks","effectByArm":[{"arm":"IDegAsp BID","deltaMin":-1.48,"sd":0.05},{"arm":"BIAsp 30 BID","deltaMin":-1.4,"sd":0.06}],"pValues":[{"comp":"OG000 vs OG001","p":"0.2430"},{"comp":"OG000 vs OG001","p":"0.2430"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":6,"exclusionCount":7},"locations":{"siteCount":42,"countries":["China"]},"refs":{"pmids":["30869183","36330105","35044568"],"seeAlso":["http://novonordisk-trials.com"]},"adverseEventsSummary":{"seriousAny":{"events":16,"n":360},"commonTop":["Upper respiratory tract infection","Diabetic retinopathy","Viral upper respiratory tract infection"]}}